Similar to aging, cancer is a state where cells lose their original identity. By applying age-reversal technologies, cancer cells can be forced to become normal again or even self-destruct, offering a novel approach to cancer treatment.

For intractable diseases like Parkinson's, the IGI takes an 'end-to-end' approach: building better disease models, discovering root causes, and simultaneously exploring multiple treatment modalities like direct CRISPR edits, cell therapies, and microbiome interventions. This tackles the entire problem, not just one piece.

The next wave of blockbuster therapies will likely be platforms addressing upstream, root-cause systems like chronic inflammation or metabolic health. This approach targets the interconnected nature of the body, influencing multiple diseases simultaneously and shifting away from the traditional single-disease treatment model.

A partnership with Novartis focuses on drug targets at the intersection of exercise and aging. The goal is to create "exercise mimetics"—drugs that replicate the health benefits of physical activity. This novel approach frames a new therapeutic class complementary to "diet mimetics" like incretin drugs.

To navigate a field where "aging" is not a recognized disease, Rejuvenate Biomed targets sarcopenia, a specific, age-related muscle-wasting condition. This provides a clear regulatory path to market. Success in this indication generates data that validates their broader platform for healthy aging, effectively using a specific disease to pioneer an entirely new therapeutic category.

Inspired by the broad benefits of drugs like GLP-1s, Gordian is proactively creating "atlases" of target effects across multiple organs (heart, kidney, liver). This strategy positions them to discover the next class of drugs that treat multiple related conditions simultaneously, a key focus for their internal pipeline.

Many major diseases are not separate issues but symptoms of the underlying aging process. By treating aging itself and restoring youthful cellular function, the body can heal itself from conditions previously thought to be incurable.

The primary hurdle in developing new fibrosis therapies is the therapeutic index. Broadly targeting the fibrotic cascade is effective but toxic because these pathways are essential for normal wound healing. The new strategy involves precisely targeting downstream pathways to improve safety without sacrificing efficacy.

Major age-related illnesses like cancer, heart disease, and dementia share a common root cause: the biological process of aging. Slowing the decline of aging would be a more effective strategy for preventing these diseases than tackling each one individually, leading to more healthy years of life.